Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Headlines

GreenLight Biosciences and Samsung Biologics to build mRNA vaccine manufacturing capacity

GreenLight Biosciences and CDMO Samsung Biologics have announced a partnership agreement, with Samsung Biologics to manufacture GreenLight’s messenger RNA COVID-19 vaccine candidate at commercial scale.

Mix-and-match COVID-19 vaccines: New trial to add to growing body of research

A new clinical trial of heterologous – or ‘mix-and-match’ – combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.

Content provided by Sumitomo Chemical Europe

Investing in high-purity guide RNA to unlock the power of CRISPR therapies

The world urgently needs new manufacturing capabilities to realise the huge potential of genome editing therapy. Equipped with CRISPR-Cas9 technology, researchers have revealed opportunities to address major unmet medical needs through genome editing...

SK investment set to bolster CBM, bring capacity to a ‘starved CGT’ marketplace

Korean company, SK, is investing in the Philadelphia-based Center for Breakthrough Medicines (CBM), a move that will support the US company in its bid to become the world's largest end-to-end cell and gene therapy contract development and manufacturing...

EMA gives green light for Pfizer/BioNTech COVID-19 vaccine in children aged 5-11

The European Medicines Agency’s human medicines committee (CHMP) has recommended granting an extension of indication for the Pfizer/BioNTech COVID-19 vaccine to include use in children aged 5 to 11.

Ncardia secures $60m to expand iPSC platform

Ncardia, a human-induced pluripotent stem cell-based (iPSC) technology company, has secured more than US$60m in capital through a strategic partnership with Kiniciti, a US based investor with a focus on the global cell and gene therapy ecosystem.